Biocon shares up 2% after ADQ pumps Rs 555 crore in subsidiary
The transaction is subject to customary condition precedents and approvals. Post the completion of this transaction, Biocon Ltd will hold 89.89 percent stake in Biocon Biologics on a fully diluted basis, the company said.
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection from ADQ, Transaction Values Biocon Biologics at ~USD 4.17 Billion BIOCON LTD. - 532523 - Shareholding for the Period Ended December 31, 2020
Biocon Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Notice of Board Meeting - Newspaper Advertisement BIOCON LTD. - 532523 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
This is to certify that the details of securities dematerialized and rematerialized during the quarter ended December 31, 2020, as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 have been furnished to all the Stock Exchanges where the shares of Biocon Limited are listed. The certificate from our RTA i.e. M/s. KFin Technologies Private Limited dated January 2, 2021, confirming the above, is enclosed for your reference. BIOCON LTD. - 532523 - Board Meeting Intimation for Intimation For The Board Meeting And Trading Window Closure
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2021 ,inter alia, to consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2020 amongst other routine matters.
Buy Biocon: target of Rs 520: Sharekhan
Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 520 in its research report dated December 28, 2020. Biocon: Street to keep an eye on CY21 launches, market share gains
Launch of a cancer drug was delayed due to Covid-19 BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US USFDA informs Biocon Biologics, Mylan of deferred action on Avastin biosimilar license application
Biocon Biologics Ltd and Mylan, a subsidiary of Viatris Inc, have been informed by the US Food and Drug Administration (USFDA) of a deferred action on the BLA for MYL-1402O, a proposed biosimilar to Avastin (bevacizumab), Biocon said in a regulatory filing.